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20% of adult population in Bangkok may be at risk for acquiring JE
when traveling to high risk/endemic area e.g. rural or upcountry.
http://dx.doi.org/10.1016/j.ijid.2016.02.905
Type: Poster Presentation
Final Abstract Number: 43.170
Session: Poster Session III
Date: Saturday, March 5, 2016
Time: 12:45-14:15
Room: Hall 3 (Posters & Exhibition)
Immunogenecity of a chimeric protein of
Bacillus anthracis protective antigen and lethal
factor in murine model
A. Varshney1,∗, N. Puranik1, M. Kumar1, A.K.
Goel2
1 Defence Research & Development Establishment,
Gwalior, India
2 Defence Research & Development Establsihment,
Gwalior, India
Background: Anthrax, a disease of bioterrorism and public
health importance is caused by the Gram positive, spore-forming
bacterium, Bacillus anthracis. Anthrax toxin, a tripartite toxin is
composed of protective antigen (PA), lethal factor (LF) or edema
factor (EF). PA is the major protein which facilitates the entry of
toxin component either of lethal factor or edema factor. Recombi-
nant PA has been a suitable target for anthrax vaccine worldwide.
However, insteadof full PA, its domains are reported toprovidepro-
tection. LF also contributes to immuno-protection against anthrax.
Therefore, in this study, a chimeric protein consisting of both, PA
and LF was developed as candidate vaccine for anthrax.
Methods&Materials: A chimerawasmadeby fusionof immun-
odominant portion of PA (Domains 2-4) and LF (Domain 1) genes. .
The construct was cloned in pET32a+ vector and expressed in E. coli
host. The recombinant chimeric protein was puriﬁed by immobi-
lized metal afﬁnity chromatography. The 4-6 week old Balb/c mice
were injected intraperitonealy with three doses of chimeric pro-
tein (20g each mouse) at two week interval. The ﬁrst dose was
given with Freund’s complete adjuvant and the subesequent doses
were given with incomplete Freund’s adjuvant. The serum IgG and
its subtypes were determined by plate ELISA.
Results: The chimeric protein (PA-LF) was puriﬁed up to homo-
geneity and the production yield was 15 mg/l of the shake ﬂask
culture. The chimera elicited good immune response against both
the toxins i.e. PA as well as LF. The end point titre of chimeric pro-
tein was 1:1024000 by plate ELISA. An antibody titre of 1:512000
was observed inmice serum for PA protein. The same serum exhib-
ited the titre of 1:256000 against LF protein. The end point titres of
IgG1, IgG2a, IgG2b and IgG3 were 1: 512000, 1:128000, 1:256000
and 1:32000, respectively. Thus, IgG1 was predominant among all
subtypes indicating that PA-LF chimera induced Th2-type immune
response
Conclusion: The chimera consisting of partial sequences of PA
and LF can be better vaccine candidate than individual PA or LF
proteins. In thepresent study, the recombinantprotein elicitedvery
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Background: Anthrax, caused by Bacillus anthracis is a well
known biothreat disease. Besides, cutaneous anthrax is a public
health disease also several countrieswhere agriculture is themajor
source of income. Being a zoonotic disease, it primarily infects her-
bivorous livestock and wildlife species and then spreads to human
through contact with infected animals or contaminated animal
products. ThevirulenceofB. anthracis is attributed to twomajor fac-
tors, i.e. a tripartite toxin and the poly-g-D-glutamic acid capsule.
The anthrax toxins are secreted as three distinct proteins, namely
protective antigen (PA), lethal factor (LF) and edema factor (EF) and
their activities have been well described. PA is the pivotal protein
of the anthrax toxin complex and therefore, has been amajor target
for vaccine development.
Methods&Materials: PA is a83kDproteinwhichhas4different
domains. In this study, the 3 different domains of PA were cloned
and expressed. The recombinant proteins were used to develop
ELISA to determine the anti-PA IgG for individual domain in human
cutaneous anthrax serumsamples. End-point titerswere deﬁned as
the highest serum dilutions that yielded an OD450nm value 2-fold
the value for the corresponding dilution of the control serum.
Results: Full PA protein (83 kD) and different domain proteins
(PAD1, 46 kD; PAD2, 43 kD and PAD4, 33 kD) were puriﬁed to the
homogeneity. A total of 41 cutaneous anthrax serum samples were
examined for immuno-reactivity with PA protein and its domains.
The whole PA protein was found to give maximum immunoreac-
tivity followed by domain 4, 2 and 1.
Conclusion: The immunoreactivity of human cutaneous serum
samples with individual PA domains showed that besides full PA
protein, individual domain 4 and 2 can also be good targets for
vaccine development as well as for serodiagnostic assays.
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